TEAEs associated with grade ≥3 hepatic toxicity were reported in two patients: one patient with SCCHN in the 0.8 mg dazostinag cohort had grade 3 blood bilirubin increased and aspartate aminotransferase (AST) increased, and one patient with NSCLC in the 2.5 mg dazostinag cohort reported grade 3 AST and alanine aminotransferase (ALT) increased. This evidence concerns the gene GPT and head and neck squamous cell carcinoma.